Literature DB >> 18690546

CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population.

Ertan Altayli1, Sezgin Gunes, Ali Faik Yilmaz, Serdar Goktas, Yuksel Bek.   

Abstract

Genetic differences in the metabolism of xenobiotics have recently been suggested as modifiers of individual susceptibility to bladder cancer (BC). The objective of this study was to investigate the relationship between bladder tumor and variants of cytochrome p450 1A2 (CYP1A2) 734 C --> A, cytochrome p450 2D6 (CYP2D6) 1934 G --> A, glutathione S-transferase M1, (GSTM1 null), glutathione S-transferase T1 (GSTT1 null), and glutathione S-transferase P1 (GSTP1) I105 V. We investigated the distribution of these polymorphisms in 135 BC patients and in 128 age and sex-matched cancer-free controls. The polymorphisms were analyzed using polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) assay and the multiplex PCR method. Genotype and allele frequencies and their associations with BC risk, demographic factors, smoking status, and tumor stage were investigated. The prevalence of GSTT1 null genotype in cases was 23%, compared with 7% in the control group (OR = 3.94, 95% CI = 1.70-9.38, P = 0.001). There was no association between the studied polymorphisms of CYP1A2, CYP2D6, GSTM1, and GSTP1 genes and BC. There was an association between smoking status and BC. These data seem to indicate that GSTT1 gene polymorphism may be associated with BC in the Turkish population studied. Further studies will be needed to clarify the role of such variation in determining susceptibility to BC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690546     DOI: 10.1007/s11255-008-9444-6

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  30 in total

Review 1.  Genetic testing for enzymes of drug metabolism: does it have clinical utility for pain medicine at the present time? A structured review.

Authors:  David A Fishbain; Dana Fishbain; John Lewis; R B Cutler; Brandly Cole; H L Rosomoff; R Steele Rosomoff
Journal:  Pain Med       Date:  2004-03       Impact factor: 3.750

2.  Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and bladder cancer susceptibility in the Turkish population.

Authors:  G A Törüner; C Akyerli; A Uçar; T Aki; N Atsu; H Ozen; M Tez; M Cetinkaya; T Ozçelik
Journal:  Arch Toxicol       Date:  2001-10       Impact factor: 5.153

3.  Association of genetic polymorphism of glutathione S-transferase M1, T1, P1 and susceptibility to bladder cancer.

Authors:  Daya Shankar Lal Srivastava; Dhruva Kumar Mishra; Anil Mandhani; Balraj Mittal; Anant Kumar; Rama Devi Mittal
Journal:  Eur Urol       Date:  2005-03-07       Impact factor: 20.096

4.  A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms.

Authors:  M Arand; R Mühlbauer; J Hengstler; E Jäger; J Fuchs; L Winkler; F Oesch
Journal:  Anal Biochem       Date:  1996-04-05       Impact factor: 3.365

5.  Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2.

Authors:  Manuela Gago-Dominguez; Douglas A Bell; Mary A Watson; Jian-Min Yuan; J Esteban Castelao; David W Hein; Kenneth K Chan; Gerhard A Coetzee; Ronald K Ross; Mimi C Yu
Journal:  Carcinogenesis       Date:  2003-03       Impact factor: 4.944

6.  Glutathione S-transferase gene polymorphisms in presbycusis.

Authors:  Nurcan Aras Ateş; Murat Unal; Lülüfer Tamer; Ebru Derici; Sevim Karakaş; Bahadir Ercan; Yavuz Selim Pata; Yücel Akbaş; Yusuf Vayisoğlu; Handan Camdeviren
Journal:  Otol Neurotol       Date:  2005-05       Impact factor: 2.311

7.  CYP1A1 and GSTM1 polymorphic genotypes in patients with prostate cancer in a Turkish population.

Authors:  Dilek Aktas; Metin Hascicek; Sinan Sozen; Haluk Ozen; Ergul Tuncbilek
Journal:  Cancer Genet Cytogenet       Date:  2004-10-01

8.  Polymorphisms of CYP1A1, GSTM1, GSTT1, and prostate cancer risk in Turkish population.

Authors:  Yavuz Silig; Hatice Pinarbasi; Sezgin Günes; Semih Ayan; Hasan Bagci; Oge Cetinkaya
Journal:  Cancer Invest       Date:  2006-02       Impact factor: 2.176

Review 9.  Gene polymorphisms in bladder cancer.

Authors:  Maria Franekova; Erika Halasova; Eva Bukovska; Jan Luptak; Dusan Dobrota
Journal:  Urol Oncol       Date:  2007-10-29       Impact factor: 3.498

Review 10.  Cytochrome P450 pharmacogenetics and cancer.

Authors:  C Rodriguez-Antona; M Ingelman-Sundberg
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

View more
  17 in total

1.  Association between the CYP1A2 polymorphisms and risk of cancer: a meta-analysis.

Authors:  Wen-Xia Sun; Ying-Hua Chen; Zhi-Zhong Liu; Jian-Jun Xie; Wei Wang; Ya-Ping Du; Yu Chen; Xu-Liang Shen; Xiao-Feng He; Li-Xia Wu; Wu Wei; Lin Zhang
Journal:  Mol Genet Genomics       Date:  2014-12-04       Impact factor: 3.291

2.  Cytochrome P4501A2 phenotype and bladder cancer risk: The Shanghai bladder cancer study.

Authors:  Li Tao; Yong-Bing Xiang; Kenneth K Chan; Renwei Wang; Yu-Tang Gao; Mimi C Yu; Jian-Min Yuan
Journal:  Int J Cancer       Date:  2011-06-21       Impact factor: 7.396

3.  Genetic polymorphisms of glutathione S-transferase M1 and bladder cancer risk: a meta-analysis of 26 studies.

Authors:  RongGui Zhang; GuangYong Xu; WenJun Chen; WeiLi Zhang
Journal:  Mol Biol Rep       Date:  2010-11-17       Impact factor: 2.316

4.  CYP1A2 polymorphisms, occupational and environmental exposures and risk of bladder cancer.

Authors:  Sofia Pavanello; Giuseppe Mastrangelo; Donatella Placidi; Marcello Campagna; Alessandra Pulliero; Angela Carta; Cecilia Arici; Stefano Porru
Journal:  Eur J Epidemiol       Date:  2010-06-18       Impact factor: 8.082

5.  Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression.

Authors:  Nagireddy Putluri; Ali Shojaie; Vihas T Vasu; Shaiju K Vareed; Srilatha Nalluri; Vasanta Putluri; Gagan Singh Thangjam; Katrin Panzitt; Christopher T Tallman; Charles Butler; Theodore R Sana; Steven M Fischer; Gabriel Sica; Daniel J Brat; Huidong Shi; Ganesh S Palapattu; Yair Lotan; Alon Z Weizer; Martha K Terris; Shahrokh F Shariat; George Michailidis; Arun Sreekumar
Journal:  Cancer Res       Date:  2011-10-11       Impact factor: 12.701

6.  Quantitative assessment of the association between glutathione S-transferase P1 Ile105Val polymorphism and bladder cancer risk.

Authors:  Zhenlong Wang; Li Xue; Tie Chong; Hecheng Li; Haiwen Chen; Ziming Wang
Journal:  Tumour Biol       Date:  2013-03-13

7.  Population study of genetic polymorphisms and superficial bladder cancer risk in Han-Chinese smokers in Shanghai.

Authors:  Hui Wen; Qiang Ding; Zu-jun Fang; Guo-wei Xia; Jie Fang
Journal:  Int Urol Nephrol       Date:  2009-04-07       Impact factor: 2.370

8.  Investigation of prognostic value of polymorphisms within estrogen metabolizing genes in Lithuanian breast cancer patients.

Authors:  Aistė Savukaitytė; Rasa Ugenskienė; Roberta Jankauskaitė; Darius Čereškevičius; Eglė Šepetauskienė; Elona Juozaitytė
Journal:  BMC Med Genet       Date:  2015-02-04       Impact factor: 2.103

9.  Detection of CYP1A1 and GSTP1 gene polymorphisms in bladder cancer patients in a Turkish population using a polymerase chain reaction-restriction fragment length polymorphism method.

Authors:  Adem Altunkol; Murat Savaş; Fuat Dilmeç; Mehmet Mazhar Utanğaç; Deniz Abat; Kemal Gümüş; İsmail Karlıdağ; Ercan Yeni
Journal:  Turk J Urol       Date:  2018-03-01

10.  CYP1A2 rs762551 polymorphism contributes to cancer susceptibility: a meta-analysis from 19 case-control studies.

Authors:  Hongge Wang; Zhi Zhang; Sugui Han; Yujuan Lu; Fumin Feng; Juxiang Yuan
Journal:  BMC Cancer       Date:  2012-11-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.